Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PROMIX - Preoperative Treatment of Breast Cancer With a Combination of Epirubicin, Docetaxel and Bevacizumab. A Translational Trial on Molecular Markers and Functional Imaging to Predict Response Early. A Phase 2 Study.

NCT00957125 is registered in ClinicalTrials.gov with Thomas Hatschek as lead sponsor.

NCT NCT00957125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00957125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PROMIX - Preoperative Treatment of Breast Cancer With a Combination of Epirubicin, Docetaxel and Bevacizumab. A Translational Trial on Molecular Markers and Functional Imaging to Predict Response Early. A Phase 2 Study.
Lead sponsor
Thomas Hatschek
Phase
Phase 2
Overall status
Unknown status
Start date
September 30, 2008
Completion date
November 30, 2016
Enrollment
151 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer